ArticleFrontiers in medicine2026
Association between the direct bilirubin to lymphocyte ratio and mortality in patients with necrotizing fasciitis: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Necrotizing fasciitis (NF) is a rapidly advancing and highly lethal infection of the soft tissues. We investigated the link between the direct bilirubin-to-lymphocyte ratio (DBLR) and 28-day mortality in NF cases. Methods: This single-center retrospective cohort study enrolled NF patients admitted to Baise People's Hospital between November 2019 and December 2025. To assess the prognostic value of DBLR, we employed restricted cubic spline (RCS) analysis, Kaplan-Meier analysis, multivariable Cox regression, subgroup analysis, and receiver operating characteristic (ROC) analysis. Results: A total of 184 patients were included. Patients in higher DBLR quartiles showed more severe hepatic, coagulation, and inflammatory abnormalities, together with higher 28-day mortality. After log Conclusions: An enhanced DBLR is linked to an increased risk of mortality within 28 days in NF. It could serve as a simple additional biomarker for early risk evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.